1. Home
  2. BIDU vs UTHR Comparison

BIDU vs UTHR Comparison

Compare BIDU & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Baidu Inc. ADS

BIDU

Baidu Inc. ADS

N/A

Current Price

$70.54

Market Cap

27.9B

Sector

Technology

ML Signal

N/A

Logo United Therapeutics Corporation

UTHR

United Therapeutics Corporation

N/A

Current Price

$575.66

Market Cap

23.9B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BIDU
UTHR
Founded
2000
1996
Country
China
United States
Employees
N/A
N/A
Industry
Computer Software: Programming Data Processing
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
27.9B
23.9B
IPO Year
2005
1999

Fundamental Metrics

Financial Performance
Metric
BIDU
UTHR
Price
$70.54
$575.66
Analyst Decision
Buy
Buy
Analyst Count
30
15
Target Price
$119.01
★ $687.14
AVG Volume (30 Days)
★ 2.1M
437.1K
Earning Date
11-16-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 13.07
EPS
N/A
★ 18.80
Revenue
N/A
★ $1,483,300,000.00
Revenue This Year
N/A
$2.15
Revenue Next Year
$6.03
$11.10
P/E Ratio
$42.45
★ $31.06
Revenue Growth
N/A
★ 2.38
52 Week Low
$70.96
$455.63
52 Week High
$165.30
$614.23

Technical Indicators

Market Signals
Indicator
BIDU
UTHR
Relative Strength Index (RSI) 26.78 47.99
Support Level N/A $559.33
Resistance Level $82.77 $586.61
Average True Range (ATR) 2.37 18.88
MACD -0.54 -3.80
Stochastic Oscillator 1.03 23.26

Price Performance

Historical Comparison
BIDU
UTHR

About BIDU Baidu Inc. ADS

Most of Baidu's revenue comes from Baidu core, with the rest coming from video-streaming subsidiary iQiyi. The firm's main businesses include online marketing services from its search engine, AI cloud infrastructure, AI applications, AI marketing, and autonomous driving.

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.

Share on Social Networks: